TafinlarĀ® receives FDA Breakthrough Therapy designation for non-small cell lung cancer with BRAF mutation
GlaxoSmithKline plc announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for TafinlarĀ® (dabrafenib) for ...